Dominique R. Talbert

Nanoparticles Containing Anti-inflammatory Agents as Chemotherapy Adjuvants II: Role of Plasma Esterases in Drug Release

Markos L. Leggas, Xiuling Lu, Philip M. Potter, Melissa D. Howard et autres

The pre-administration of the anti-inflammatory drugs dexamethasone (DEX) and cortisone acetate reduces toxicity and enhances efficacy of anticancer agents in murine models and in human clinical trials (1–5). We previously reported on the formulation of the lipophilic dexamethasone palmitate ester (DEX-P) in …

Cardiac safety profile of pan-HER inhibitors afatinib and neratinib using a multi-parameter in vitro screening approach

Kimberly R. Doherty, Dominique R. Talbert, Patricia B. Trusk, Scott A. Shell et autres

us (code pays fourni par la source)

Abstract 2611: A multi-parameter in vitro screen demonstrates increased cardiac toxicity with pan-HER inhibitors afatinib and neratinib when used in combination with chemotherapy

Dominique R. Talbert, Kimberly R. Doherty, Patricia B. Trusk, Diarmuid Martin Moran et autres

Abstract The human epidermal growth factor receptor 2 (HER2) oncogene is amplified and overexpressed in 25 to 30% of breast cancers and is associated with poor prognosis. Currently, two HER2-targeting agents have been FDA-approved for the treatment of these breast cancers: trastuzumab …

us (code pays fourni par la source)

Structural and functional screening in human induced-pluripotent stem cell-derived cardiomyocytes accurately identifies cardiotoxicity of multiple drug types

Kimberly R. Doherty, Dominique R. Talbert, Patricia B. Trusk, Diarmuid Martin Moran et autres

us (code pays fourni par la source)

A Multi-parameter In Vitro Screen in Human Stem Cell-Derived Cardiomyocytes Identifies Ponatinib-Induced Structural and Functional Cardiac Toxicity

Dominique R. Talbert, Kimberly R. Doherty, Patricia B. Trusk, Diarmuid Martin Moran et autres

Ponatinib, a multi-targeted TKI and potent pan-ABL inhibitor, approved for the treatment of Ph + ALL and CML, was temporarily withdrawn from the U.S. market due to severe vascular adverse events. Cardiac-specific toxicities including myocardial infarction, severe congestive heart failure, and cardiac …

gb, us (code pays fourni par la source)

Abstract 3674: Targeted oncology therapeutics show unique cardiotoxic profiles: Ponatinib as a case study

Dominique R. Talbert, Kimberly R. Doherty, Patricia B. Trusk, Diarmuid Martin Moran et autres

Abstract Although tyrosine kinase inhibitors (TKI) have greatly improved the treatment and prognosis of multiple cancer types, unexpected clinical cardiotoxicity has occurred with some of these agents that was not predicted by standard preclinical toxicity assessment methods. Since cardiotoxicity with TKI are …

us (code pays fourni par la source)

Abstract C280: Oncology therapeutics show unique cardiotoxic profiles in human cardiac cells.

Dominique R. Talbert, Kimberly R. Doherty, Diarmuid Martin Moran, Robert Wappell et autres

Abstract Tyrosine Kinase Inhibitors (TKI) have greatly improved the treatment and prognosis of multiple cancer types. However unexpected clinical cardiotoxicity has been shown with some of these agents that was not wholly predicted by current preclinical toxicity assessment methods. Since cardiotoxicity with …

us (code pays fourni par la source)

Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes

Kimberly R. Doherty, Robert L. Wappel, Dominique R. Talbert, Patricia B. Trusk et autres

us (code pays fourni par la source)

Abstract 3101: The Role of MYC and the miR-17∼92 cluster in histone deacetylase inhibitor-induced apoptosis.

Dominique R. Talbert, Robert L. Wappel, Diarmuid Martin Moran, Scott A. Shell et autres

Abstract In recent years histone deacetylase inhibitors (HDACi's) have emerged as promising therapeutics for cancer. While favorable responses to HDACi's as single agents have been shown in several hematological malignancies, very little efficacy has been demonstrated in solid tumors. c-Myc (Myc), an …

us (code pays fourni par la source)

Abstract 4423: Implications for cardiotoxicity with targeted therapies.

Kimberly R. Doherty, Robert L. Wappel, Dominique R. Talbert, Patricia B. Trusk et autres

Abstract Tyrosine kinase inhibitors (TKi) have greatly improved the treatment and prognosis of multiple cancer types. However, unexpected cardiotoxicity has arisen that was not wholly predicted by current FDA mandated pre-clinical tests. Thus a more robust tool to predict the cardiotoxic potential …

us (code pays fourni par la source)

The Role of Myc and the miR-17~92 Cluster in Histone Deacetylase Inhibitor Induced Apoptosis of Solid Tumors

Dominique R. Talbert, Robert L. Wappel, Diarmuid Martin Moran, Scott A. Shell et autres

In recent years histone deacetylase inhibitors (HDACi’s) have emerged as promising therapeutics for cancer. While favorable responses to HDACi’s as single agents have been shown in several hematological malignancies, very little efficacy has been demonstrated in solid tumors. c-Myc (Myc), an oncoprotein …

us (code pays fourni par la source)

Abstract 1146: Multiple HDAC inhibitors (HDACi) reduce the expression of the oncogenic miR-17∼92 cluster; a pan HDACi class effect

Dominique R. Talbert, Xiaodong Peng, Scott A. Shell, Sarah S. Bacus

Abstract miR-17∼92 is an oncogenic polycistronic cluster encoding six mature miRNAs (MIR-17, MIR-20A, MIR-18A, MIR-19A, MIR-19B, and MIR-92A). This oncogenic cluster is driven by MYC activity and is highly-expressed in many tumor types where it has been shown to promote tumorigenesis through …

us (code pays fourni par la source)